{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:29:19Z","timestamp":1793860159512,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guizhou Provincial Basic Research Program","award":["QianKeHeJiChu-MS [2026] 926"],"award-info":[{"award-number":["QianKeHeJiChu-MS [2026] 926"]}]},{"name":"National Natural Science Foundation of China","award":["22461050"],"award-info":[{"award-number":["22461050"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Zunyi Medical University","award":["No. 18zy-003"],"award-info":[{"award-number":["No. 18zy-003"]}],"id":[{"id":"https:\/\/ror.org\/00g5b0g93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Education Department of Guizhou Province","award":["No. [2024]334"],"award-info":[{"award-number":["No. [2024]334"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11701-4","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:48:44Z","timestamp":1787212124000},"page":"10703-10716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, and biological evaluation of novel trifluoromethyl-substituted quinolinone derivatives targeting triple-negative breast cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Mei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-9040","authenticated-orcid":false,"given":"Xueyu","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"11701_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"11701_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, Huang L, Liu C-C, Shao Z-M, Yu K-D (2025) Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 10:49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4","journal-title":"Signal Transduct Target Ther"},{"key":"11701_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK (2024) Analysis of breast cancer mortality in the US\u20141975 to 2019. JAMA 331:233\u2013241. https:\/\/doi.org\/10.1001\/jama.2023.25881","journal-title":"JAMA"},{"key":"11701_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K (2023) Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16:100. https:\/\/doi.org\/10.1186\/s13045-023-01497-3","journal-title":"J Hematol Oncol"},{"key":"11701_CR5","doi-asserted-by":"publisher","first-page":"v30","DOI":"10.1093\/neuonc\/noaf201.0115","volume":"27","author":"S Agarwal","year":"2025","unstructured":"Agarwal S, Mehranpour P, Chawla A, Vaish C, Wadehra M, Yang I (2025) Biom-27. Predictive biomarkers of brain metastasis in triple-negative breast cancer: clinicopathological correlates and emerging evidence. Neuro-oncol 27:v30\u2013v30. https:\/\/doi.org\/10.1093\/neuonc\/noaf201.0115","journal-title":"Neuro-oncol"},{"key":"11701_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103730","author":"P Dyer","year":"2024","unstructured":"Dyer P, Xie J, Tran PK, Byrne K (2024) Survival outcomes for women with a solitary extracranial metastasis from breast cancer. Breast. https:\/\/doi.org\/10.1016\/j.breast.2024.103730","journal-title":"Breast"},{"key":"11701_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K (2023) Metastasis. Cell 186:1564\u20131579. https:\/\/doi.org\/10.1016\/j.cell.2023.03.003","journal-title":"Metastasis Cell"},{"key":"11701_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41413-023-00260-1","volume":"11","author":"Y Huang","year":"2023","unstructured":"Huang Y, Wang H, Yue X, Li X (2023) Bone serves as a transfer station for secondary dissemination of breast cancer. Bone Res 11:21. https:\/\/doi.org\/10.1038\/s41413-023-00260-1","journal-title":"Bone Res"},{"key":"11701_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A, Luo P, Cheng Q, Xu H, Han X (2024) Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther 9:270. https:\/\/doi.org\/10.1038\/s41392-024-01955-5","journal-title":"Signal Transduct Target Ther"},{"key":"11701_CR10","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674","journal-title":"BMJ"},{"key":"11701_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-022-01781-5","volume":"82","author":"I Schlam","year":"2022","unstructured":"Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM (2022) Emerging targeted therapies for early breast cancer. Drugs 82:1437\u20131451. https:\/\/doi.org\/10.1007\/s40265-022-01781-5","journal-title":"Drugs"},{"key":"11701_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"R Hong","year":"2022","unstructured":"Hong R, Xu B (2022) Breast cancer: an up-to-date review and future perspectives. Cancer Commun 42:913\u2013936. https:\/\/doi.org\/10.1002\/cac2.12358","journal-title":"Cancer Commun"},{"key":"11701_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cac2.12282","volume":"42","author":"E Polonio-Alcal\u00e1","year":"2022","unstructured":"Polonio-Alcal\u00e1 E, Sol\u00e9-S\u00e1nchez S, Mu\u00f1oz-Guardiola P, Meg\u00edas-Roda E, Perez-Montoyo H, Yeste-Velasco M, Alf\u00f3n J, Lizcano JM, Dom\u00e8nech C, Ruiz-Mart\u00ednez S, Puig T (2022) ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. Cancer Commun 42:567\u2013571. https:\/\/doi.org\/10.1002\/cac2.12282","journal-title":"Cancer Commun"},{"key":"11701_CR14","doi-asserted-by":"publisher","first-page":"101358","DOI":"10.1016\/j.mtbio.2024.101358","volume":"29","author":"J-x Qiao","year":"2024","unstructured":"Qiao J-x, Guo D-y, Tian H, Wang Z-p, Fan Q-q, Tian Y, Sun J, Zhang X-f, Zou J-b, Cheng J-x, Luan F, Zhai B-t (2024) Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer. Mater Today Bio 29:101358. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101358","journal-title":"Mater Today Bio"},{"key":"11701_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","volume":"318","author":"L Zhao","year":"2020","unstructured":"Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H (2020) Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release 318:1\u201315. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.005","journal-title":"J Control Release"},{"key":"11701_CR16","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1021\/acs.jnatprod.0c00599","volume":"83","author":"P Zhu","year":"2020","unstructured":"Zhu P, Qian J, Xu Z, Meng C, Liu J, Shan W, Zhu W, Wang Y, Yang Y, Zhang W, Zhang Y, Ling Y (2020) Piperlonguminine and piperine analogues as TrxR inhibitors that promote ROS and autophagy and regulate p38 and Akt\/mTOR signaling. J Nat Prod 83:3041\u20133049. https:\/\/doi.org\/10.1021\/acs.jnatprod.0c00599","journal-title":"J Nat Prod"},{"key":"11701_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2025.1638489","author":"LH Al-Wahaibi","year":"2025","unstructured":"Al-Wahaibi LH, Abou-Zied HAA, Nieger M, Br\u00e4se S, Youssif BGMG, Tawfeek HN (2025) Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR\/HER-2 inhibitors. Front Chem. https:\/\/doi.org\/10.3389\/fchem.2025.1638489","journal-title":"Front Chem"},{"key":"11701_CR18","doi-asserted-by":"publisher","first-page":"e70176","DOI":"10.1002\/ddr.70176","volume":"86","author":"EAE El-Helw","year":"2025","unstructured":"El-Helw EAE, Mousa MHA, Ghareeb EA, Mahmoud NFH, Sharaky M, El-Bordany EA, Khatib AOA, Soliman EA, Alnajjar R, Al-Karmalawy AA (2025) Multi-target rational design and synthesis of some 2-quinolinone antitumor candidates downregulating the expression of EGFR, VEGFR-2, and telomerase with apoptotic potential. Drug Dev Res 86:e70176. https:\/\/doi.org\/10.1002\/ddr.70176","journal-title":"Drug Dev Res"},{"key":"11701_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2026.118783","author":"S Thadkapally","year":"2026","unstructured":"Thadkapally S, Karanam LS, Kumar BK, Sharma P, Vankudoth J (2026) 2- and 4-quinolones as emerging anticancer scaffolds: Recent synthetic developments, SAR insights, and mechanistic perspective. Eur J Med Chem. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118783","journal-title":"Eur J Med Chem"},{"key":"11701_CR20","doi-asserted-by":"publisher","first-page":"109033","DOI":"10.1016\/j.bioorg.2025.109033","volume":"165","author":"N Azzman","year":"2025","unstructured":"Azzman N, Gill MSA, Abdullah N, Gutierrez DA, Varela-Ramirez A, Sanchez-Michael LA, Lopez-Saenz JA, Taib MNAM, Shah SAA, Aguilera RJ, Ahemad N (2025) Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells. Bioorg Chem 165:109033. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109033","journal-title":"Bioorg Chem"},{"key":"11701_CR21","doi-asserted-by":"publisher","first-page":"38497","DOI":"10.1038\/s41598-025-22255-0","volume":"15","author":"EA Ghaith","year":"2025","unstructured":"Ghaith EA, Elnaggar NN, Hamama WS (2025) Rational design, synthesis of some quinolinone-Schiff bases\/ pyridazino[4,5-c]quinolinones with potent anti-lung cancer and antituberculosis performance. Sci Rep 15:38497. https:\/\/doi.org\/10.1038\/s41598-025-22255-0","journal-title":"Sci Rep"},{"key":"11701_CR22","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1007\/s00289-022-04238-7","volume":"80","author":"MA Mostafa","year":"2023","unstructured":"Mostafa MA, Ismail MM, Morsy JM, Hassanin HM, Abdelrazek MM (2023) Synthesis, characterization, anticancer, and antioxidant activities of chitosan Schiff bases bearing quinolinone or pyranoquinolinone and their silver nanoparticles derivatives. Polym Bull (Berlin) 80:4035\u20134059. https:\/\/doi.org\/10.1007\/s00289-022-04238-7","journal-title":"Polym Bull (Berlin)"},{"key":"11701_CR23","doi-asserted-by":"publisher","first-page":"13300","DOI":"10.3390\/ijms241713300","volume":"24","author":"EM El-Sheref","year":"2023","unstructured":"El-Sheref EM, Br\u00e4se S, Tawfeek HN, Alasmary FA, Youssif BGM (2023) Synthesis, antioxidant and antiproliferative actions of 4-(1,2,3-Triazol-1-yl)quinolin-2(1H)-ones as multi-target inhibitors. Int J Mol Sci 24:13300","journal-title":"Int J Mol Sci"},{"key":"11701_CR24","doi-asserted-by":"publisher","first-page":"117380","DOI":"10.1016\/j.ejmech.2025.117380","volume":"287","author":"S Ali","year":"2025","unstructured":"Ali S, Tian X, Meccia SA, Zhou J (2025) Highlights on U.S. FDA-approved halogen-containing drugs in 2024. Eur J Med Chem 287:117380. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117380","journal-title":"Eur J Med Chem"},{"key":"11701_CR25","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1021\/acs.jmedchem.5c02359","volume":"69","author":"P Bhattarai","year":"2026","unstructured":"Bhattarai P, Trombley TA, Altman RA (2026) Metabolic stability of fluorinated small molecules: a physical organic chemistry perspective. J Med Chem 69:1916\u20131941. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02359","journal-title":"J Med Chem"},{"key":"11701_CR26","doi-asserted-by":"publisher","first-page":"10799","DOI":"10.1021\/acs.chemrev.5c00890","volume":"125","author":"T Lectka","year":"2025","unstructured":"Lectka T, Matsumoto K, Riedel S (2025) Introduction: fluorine-specific iiteractions. Chem Rev 125:10799\u201310801. https:\/\/doi.org\/10.1021\/acs.chemrev.5c00890","journal-title":"Chem Rev"},{"key":"11701_CR27","doi-asserted-by":"publisher","first-page":"116446","DOI":"10.1016\/j.ejmech.2024.116446","volume":"271","author":"Z-X Niu","year":"2024","unstructured":"Niu Z-X, Hu J, Sun J-F, Wang Y-T (2024) Fluorine in the pharmaceutical industry: synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications. Eur J Med Chem 271:116446. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116446","journal-title":"Eur J Med Chem"},{"key":"11701_CR28","doi-asserted-by":"publisher","first-page":"109780","DOI":"10.1016\/j.cclet.2024.109780","volume":"35","author":"Q Wang","year":"2024","unstructured":"Wang Q, Bian Y, Dhawan G, Zhang W, Sorochinsky AE, Makarem A, Soloshonok VA, Han J (2024) FDA approved fluorine-containing drugs in 2023. Chin Chem Lett 35:109780. https:\/\/doi.org\/10.1016\/j.cclet.2024.109780","journal-title":"Chin Chem Lett"},{"key":"11701_CR29","doi-asserted-by":"publisher","first-page":"e202301077","DOI":"10.1002\/anie.202301077","volume":"62","author":"Z Wang","year":"2023","unstructured":"Wang Z, Felstead HR, Troup RI, Linclau B, Williamson PTF (2023) Lipophilicity modulations by fluorination correlate with membrane partitioning. Angew Chem Int Ed 62:e202301077. https:\/\/doi.org\/10.1002\/anie.202301077","journal-title":"Angew Chem Int Ed"},{"key":"11701_CR30","doi-asserted-by":"publisher","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","volume":"64","author":"Y Li","year":"2021","unstructured":"Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L (2021) Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer. J Med Chem 64:12022\u201312048. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00678","journal-title":"J Med Chem"},{"key":"11701_CR31","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1021\/acs.jmedchem.7b00701","volume":"60","author":"T Rawling","year":"2017","unstructured":"Rawling T, Choucair H, Koolaji N, Bourget K, Allison SE, Chen Y-J, Dunstan CR, Murray M (2017) A novel arylurea fatty acid that targets the mitochondrion and depletes cardiolipin to promote killing of beast cancer cells. J Med Chem 60:8661\u20138666. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00701","journal-title":"J Med Chem"},{"key":"11701_CR32","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1021\/acs.jmedchem.6b00943","volume":"59","author":"C-H Zhang","year":"2016","unstructured":"Zhang C-H, Chen K, Jiao Y, Li L-L, Li Y-P, Zhang R-J, Zheng M-W, Zhong L, Huang S-Z, Song C-L, Lin W-T, Yang J, Xiang R, Peng B, Han J-H, Lu G-W, Wei Y-Q, Yang S-Y (2016) From lead to drug candidate: optimization of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as agents for the treatment of triple negative breast cancer. J Med Chem 59:9788\u20139805. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00943","journal-title":"J Med Chem"},{"key":"11701_CR33","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1021\/acs.orglett.4c00717","volume":"26","author":"P Guo","year":"2024","unstructured":"Guo P, Pu G, Wang G, Zeng L-Y, Li W-P, Li X, Zhou P-P, He C-Y (2024) Halogen-bond-promoted direct cross-coupling of trifluoromethylated alkyl bromides with coumarins\/quinolinones: unraveling trifluoromethyl effects. Org Lett 26:3097\u20133102. https:\/\/doi.org\/10.1021\/acs.orglett.4c00717","journal-title":"Org Lett"},{"key":"11701_CR34","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1021\/acs.orglett.2c00425","volume":"24","author":"P Guo","year":"2022","unstructured":"Guo P, Tao M, Xu W-W, Wang A-J, Li W, Yao Q, Tong J, He C-Y (2022) Synthesis of secondary trifluoromethylated alkyl bromides using 2-bromo-3,3,3-trifluoropropene as a radical acceptor. Org Lett 24:2143\u20132148. https:\/\/doi.org\/10.1021\/acs.orglett.2c00425","journal-title":"Org Lett"},{"key":"11701_CR35","doi-asserted-by":"publisher","first-page":"107183","DOI":"10.1016\/j.compbiomed.2023.107183","volume":"163","author":"A Mijit","year":"2023","unstructured":"Mijit A, Wang X, Li Y, Xu H, Chen Y, Xue W (2023) Mapping synthetic binding proteins epitopes on diverse protein targets by protein structure prediction and protein-protein docking. Comput Biol Med 163:107183. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107183","journal-title":"Comput Biol Med"},{"key":"11701_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"P \u015aled\u017a","year":"2018","unstructured":"\u015aled\u017a P, Caflisch A (2018) Protein structure-based drug design: from docking to molecular dynamics. Curr Opin Struct Biol 48:93\u2013102. https:\/\/doi.org\/10.1016\/j.sbi.2017.10.010","journal-title":"Curr Opin Struct Biol"},{"key":"11701_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.sbi.2020.07.001","volume":"64","author":"IA Vakser","year":"2020","unstructured":"Vakser IA (2020) Challenges in protein docking. Curr Opin Struct Biol 64:160\u2013165. https:\/\/doi.org\/10.1016\/j.sbi.2020.07.001","journal-title":"Curr Opin Struct Biol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11701-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:05:25Z","timestamp":1793858725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11701-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11701"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11701-4","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}